Physician profile
Shen Li
NPI 1568236875
$1,404.21
in general payments reported to CMS, 2019-2025
16 companies · $1,404 in 2025
The $1,404 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,326 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,326.22 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $264.76 | 2025 | Venclexta, Polivy, Itovebi |
| Daiichi Sankyo INC. | $197.97 | 2025 | Datroway, Enhertu |
| Stemline Therapeutics INC. | $186.20 | 2025 | Orserdu |
| Pfizer INC. | $145.33 | 2025 | |
| Beone Medicines USA, INC. | $125.00 | 2025 | Brukinsa |
| Janssen Biotech, INC. | $119.61 | 2025 | Erleada, Darzalex, Talvey |
| Gilead Sciences, INC. | $71.86 | 2025 | Trodelvy |
| Taiho Oncology, INC. | $61.31 | 2025 | |
| Eisai INC. | $56.14 | 2025 | |
| Puma Biotechnology, INC. | $48.46 | 2025 | |
| Incyte Corporation | $38.16 | 2025 | Monjuvi, Zynyz |
| Merck Sharp & Dohme LLC | $22.86 | 2025 | |
| Genmab U.S., INC. | $18.87 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.53 | 2025 | Ninlaro |
| Sumitomo Pharma America, INC. | $15.86 | 2025 | Orgovyx |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $14.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shen Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.